TRANSMIT: Difference between revisions

Revision as of 16:52, 8 March 2017

TRANSMIT

TRANSMIT - TRANSlating the role of MItochondria in Tumorigenesis

‎

Cancer is not only a genetic, but also a metabolic disease

The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidence places mitochondria as key actors in cancer metabolic restructuring, not only because these organelles play a crucial role in energy production and formation of biosynthetic intermediates, but also because occurrence of mutations in both nuclear and mtDNA encoding metabolic enzymes is associated with different types of cancer.

Objectives

TRANSMIT aims to dissect the metabolic remodeling in human cancers, placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies.

TRANSMIT fosters the communication of this emerging field to the patients and their families. Accordingly, TRANSMIT will create a network of seven countries, including world-leading basic science and clinical centers of excellence, several industrial partners with up-to-date technologies, as well as non-profit foundations and associations who care for cancer patients.

By creating the critical mass of scientific excellence, TRANSMIT will allow to transfer the current knowledge into the wide field of cancer research, translating scientific and technical advances to the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.

TRANSMIT key methodologies and key objectives: The project is structured in three scientific WPs. For each WP, several ESRs are recruited as indicated below the WP title. Scientific WPs share the key methodologies indicated within the four sectors of the romboid in light grey. The implementation of key methodologies in pairs allows the achievement of the key objectives indicated by the dark grey arrowheads.

Coordinator

Alma Mater Studiorum – Università di Bologna - IT

Submitted by Anna-Maria Porcelli and Serena Paterlini (University of Bologna)

List of participants

Alma Mater Studiorum – Università di Bologna - IT (lead partner)
Universite Catholique de Louvain - BE
OROBOROS INSTRUMENTS GmbH - AT
Justus Liebig Universität Giessen - DE
Gemeinnützige Salzburger Landeskliniken Betriebsgesellschaft - AT
Karolinska Institutet - SE
The Chancellor, Masters and Scholars of the University of Cambridge - UK
Association pour le développement de l'enseignement et des recherches aupres des universities et des enterprises d’aquitaine - FR
Biocrates Life Sciences AG - AT
AvantiCell Science Ltd - UK

Partner organisations

Fondazione Umberto Veronesi - IT
Innova SRL - IT
CEUB Il Centro Residenziale Universitario di Bertinoro (Ce.U.B.) - IT
Dynamo Academy srl Impresa Sociale – IT

Official announcement of the Marie-Curie Skłodowska Action TRANSMIT: http://cordis.europa.eu/project/rcn/205395_en.html
OROBOROS MitoFit Research Laboratory

@@ Line 8: / Line 8: @@
 [[Image:European_commission_logo.png‎|right|150px|European commission]]
 '''Cancer is not only a genetic, but also a metabolic disease'''
-:::: The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidences place mitochondria as key actors in cancer metabolic restructuring, not only because these organelles have a crucial role in the energy and biosynthetic intermediates production but also because occurrence of mutations in metabolic enzymes encoded by both nuclear and mitochondrial DNA has been associated to different types of cancer.
+:::: The consolidation of the knowledge that cancer is not only a genetic, but also a metabolic disease, has led scientists to investigate the intricate metabolic plasticity that transformed cells must undergo to survive the adverse tumor microenvironment conditions, and the contribution of oncogenes and tumor suppressors in shaping metabolism. In this scenario, genetic, biochemical and clinical evidence places mitochondria as key actors in cancer metabolic restructuring, not only because these organelles play a crucial role in energy production and formation of biosynthetic intermediates, but also because occurrence of mutations in both nuclear and mtDNA encoding metabolic enzymes is associated with different types of cancer.
@@ Line 15: / Line 15: @@
 :::: '''TRANSMIT aims to dissect the metabolic remodeling in human cancers''', placing the focus on the role of mitochondria and bridging basic research to the improvement/development of therapeutic strategies.
-:::: Further, '''TRANSMIT fosters the communication''' of this emerging field to the patients and their families. To these aims, TRANSMIT will create a network of seven different countries, among which world-leading basic science and clinical centers of excellence, several industrial partners with up-to-date omics technologies, as well as non-profit foundations and associations who care for cancer patients.
+:::: '''TRANSMIT fosters the communication''' of this emerging field to the patients and their families. Accordingly, TRANSMIT will create a network of seven countries, including world-leading basic science and clinical centers of excellence, several industrial partners with up-to-date technologies, as well as non-profit foundations and associations who care for cancer patients.
-:::: By creating the critical mass of scientific excellence, '''TRANSMIT will allow to transfer the current knowledge''' into the wide field of cancer research, translating scientific and technical advances into the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.
+:::: By creating the critical mass of scientific excellence, '''TRANSMIT will allow to transfer the current knowledge''' into the wide field of cancer research, translating scientific and technical advances to the education and training of eleven Early Stage Researchers. TRANSMIT will implement training-through-research dedicated to unravel the metabolic features of cancer, as well as to provide a full portfolio of complementary skills through the creation of a network of basic, translational and industrial laboratories, devoted to a multidisciplinary/multisectorial education of young scientists.
+:::: '''TRANSMIT key methodologies and key objectives''': The project is structured in three scientific WPs. For each WP, several ESRs are recruited as indicated below the WP title. Scientific WPs share the key methodologies indicated within the four sectors of the romboid in light grey. The implementation of key methodologies in pairs allows the achievement of the key objectives indicated by the dark grey arrowheads.
-:::: '''TRANSMIT key methodologies and key objectives'''
+:::: [[Image:TRANSMIT key methodologies and key objectives.jpg|750px|Key methodologies and key objectives]]
-::::The proposal envisions three scientific WPs. For each WP, several ESRs are recruited as indicated below the WP title. Scientific WPs share the key methodologies indicated within the four sectors of the romboid in light grey. The implementation of key methodologies in pairs allows the achievement of the key objectives indicated by the dark grey arrowheads.
-:::: [[Image:TRANSMIT key methodologies and key objectives.jpg|750px|Key methodologies and key objectives]]
 == Coordinator ==
@@ Line 31: / Line 30: @@
-== List of Participants ==
+== List of participants ==
-::::TRANSMIT is a multi-partner project that intends to mobilize the critical mass of expertise, by linking partners from 7 different countries, among which world-leading basic science and clinical centers of excellence, 4 SMEs as full partners, as well as non-profit foundations with a long-lasting history of dealing with the societal consequences of cancer in patients and their families.
-::::*	[http://www.unibo.it/en/ Alma Mater Studiorum – Università di Bologna] - IT
+::::*	[http://www.unibo.it/en/ Alma Mater Studiorum – Università di Bologna] - IT (lead partner)
 ::::*	[http://www.uclouvain.be/index.html/ Universite Catholique de Louvain] - BE
 ::::*	[http://wiki.oroboros.at/index.php/OROBOROS_INSTRUMENTS/ OROBOROS INSTRUMENTS GmbH] - AT
@@ Line 75: / Line 70: @@
-Official announcement of the Marie-Curie Skłodowska Action TRANSMIT: http://cordis.europa.eu/project/rcn/205395_en.html
+::::* Official announcement of the Marie-Curie Skłodowska Action TRANSMIT: http://cordis.europa.eu/project/rcn/205395_en.html
+::::* [[OROBOROS MitoFit_Laboratory |OROBOROS MitoFit Research Laboratory]]